TobraDex · DIN 00778907 · 0.3% & 0.1% · Oph suspension
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778907
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2018-05-10 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
TobraDex: Formulary list price $2.25 per unit (the source does not state the unit; exact figure $2.2500). What the ministry pays, not the patient.
Ministry pays: $2.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778907)
Source record
DIN 00778907: TobraDex
Raw flags: sec3=Y
Item: 520404031; group id 585; item number 1542; lccId None; manufacturer id NOV
Source form: Oph Susp; strength: 0.3% & 0.1%
Recorded listing: General benefit
Source prices (unrounded): $2.2500; ministry $2.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778907
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11068
Shortage status: not checked (no credentials)